High-alert medications for pediatric patients: an international modified Delphi study

被引:27
|
作者
Maaskant, Jolanda M. [1 ]
Eskes, Anne [2 ,4 ]
van Rijn-Bikker, Petra [3 ]
Bosman, Diederik [1 ]
van Aalderen, Wim [1 ]
Vermeulen, Hester [2 ,4 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, NL-1100 DE Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Qual Assurance & Proc, NL-1100 DE Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Clin Pharm, NL-1100 DE Amsterdam, Netherlands
[4] Amsterdam Sch Hlth Profess, Dept Nursing, Amsterdam, Netherlands
关键词
children; harm; high-alert; medication safety; pediatrics; ADVERSE DRUG EVENTS; NEONATAL INTENSIVE-CARE; ORDER ENTRY; HOSPITALIZED-PATIENTS; ERRORS; SAFETY; EPIDEMIOLOGY; CHEMOTHERAPY; PREVENTION; STRATEGIES;
D O I
10.1517/14740338.2013.825247
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The available knowledge about high-alert medications for children is limited. Because children are particularly vulnerable to medication errors, a list of high-alert medication specifically for children would help to develop effective strategies to prevent patient harm. Therefore, we conducted an international modified Delphi study and validated the results with reports on medication incidents in children based on national data. Objective: The objective of this study was to generate an internationally accepted list of high-alert medications for a pediatric inpatient population from birth to 18-years old. Results: The rating panel consisted of 34 experts from 13 countries. In total, 14 medications and 4 medication classes were included with the predefined level of consensus of 75%. The high-alert medications were: amiodarone, digoxin, dopamine, epinephrine, fentanyl, gentamycin, heparine, insulin, morphine, norepinephrine, phenytoin, potassium, propofol and tacrolimus. The high-alert medication classes included in the final list were: chemotherapeutic drugs, immunosuppressive medications, lipid/total parenteral nutrition and opioids. Conclusion: An international group of experts defined 14 medications and 4 medication classes as high-alert for children. This list might be helpful as a starting point for individual hospitals to develop their own high-alert list tailored to their unique situation.
引用
收藏
页码:805 / 814
页数:10
相关论文
共 50 条
  • [31] Polypharmacy and high-alert medications in patients with nasally placed feeding tube on admission and at hospital discharge: Multicenter cross-sectional study
    Gimenes, Fernanda Raphael Escobar
    de Freitas, Juliana Santana
    Koepp, Janine
    do Prado, Patricia Rezende
    Menezes, Rochele Mosmann
    Leclerc, Jacinthe
    de Medeiros, Adriane Pinto
    Teixeira, Thalyta Cardoso Alux
    Carvalho, Rhanna Emanuela Fontenele Lima
    Zanetti, Maria Olivia Barboza
    Miasso, Adriana Inocenti
    Gonella, Jennifer Midiani
    EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY, 2024, 15
  • [32] Harm Prevalence Due to Medication Errors Involving High-Alert Medications: A Systematic Review
    Sodre Alves, Barbara Manuella Cardoso
    de Andrade, Tamara Natasha Gonzaga
    Cerqueira Santos, Sabrina
    Goes, Aline Santana
    Santos, Adriano da Silva
    de Lyra Junior, Divaldo Pereira
    de Oliveira Filho, Alfredo Dias
    JOURNAL OF PATIENT SAFETY, 2021, 17 (01) : E1 - E9
  • [33] Impact of a clinical decision support system for high-alert medications on the prevention of prescription errors
    Lee, JaeHo
    Han, Hyewon
    Ock, Minsu
    Lee, Sang-il
    Lee, SunGyo
    Jo, Min-Woo
    INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, 2014, 83 (12) : 929 - 940
  • [34] Utility of a trigger tool (TRIGGER-CHRON) to detect adverse events associated with high-alert medications in patients with multimorbidity
    Jose Otero, Maria
    Toscano Guzman, Maria Dolores
    Galvan-Banqueri, Mercedes
    Martinez-Sotelo, Jesus
    Dolores Santos-Rubio, Maria
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (E1) : E41 - E46
  • [35] BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications
    Hira, Daiki
    Terada, Tomohiro
    BIOCHEMICAL PHARMACOLOGY, 2018, 147 : 201 - 210
  • [36] Developing a Comprehensive Framework of Safeguarding Strategies to Address Anticipated Errors With Organizational High-Alert Medications
    Booth, Jennifer P.
    Hartman, Amber D.
    HOSPITAL PHARMACY, 2024, 59 (01) : 47 - 55
  • [37] Evaluation of the Personalized Bar-code Identification Card to Verify High-Risk, High-Alert Medications
    Thomas, Maria
    CIN-COMPUTERS INFORMATICS NURSING, 2013, 31 (09) : 412 - 421
  • [38] Identifying High-alert Medications in a University Hospital by Applying Data From the Medication Error Reporting System
    Tyynismaa, Lotta
    Honkala, Anni
    Airaksinen, Marja
    Shermock, Kenneth
    Lehtonen, Lasse
    JOURNAL OF PATIENT SAFETY, 2021, 17 (06) : 417 - 424
  • [39] High-alert medications for hospitalised paediatric patients - a two-step survey among paediatric clinical expert pharmacists in Germany
    Schilling, S.
    Koeck, J. A.
    Kontny, U.
    Orlikowsky, T.
    Erdmann, H.
    Eisert, A.
    PHARMAZIE, 2022, 77 (06): : 207 - 215
  • [40] Differences exist in what pharmacists, nurses consider high-alert medications in acute-care settings
    Blank, Christine
    FORMULARY, 2012, 47 (04) : 131 - 131